SS
ABCL icon

SBI Securities’s AbCellera Biologics ABCL Stock Holding History

SBI Securities’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.5K Buy
12,551
+4,023
+47% +$19.7K ﹤0.01% 924
2026
Q1 		$29.8K Buy
8,528
+5,901
+225% +$21.2K ﹤0.01% 1301
2025
Q4 		$8.98K Sell
2,627
-655
-20% -$2.92K ﹤0.01% 1758
2025
Q3 		$16.5K Sell
3,282
-2,361
-42% -$10.4K ﹤0.01% 1535
2025
Q2 		$19.4K Buy
5,643
+2,723
+93% +$6.78K ﹤0.01% 1421
2025
Q1 		$6.51K Buy
2,920
+529
+22% +$1.52K ﹤0.01% 1789
2024
Q4 		$7.01K Buy
+2,391
New +$6.66K ﹤0.01% 1791

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

SBI Securities's ABCL Position: Q2 2026 in Review

SBI Securities increased its AbCellera Biologics (ABCL) stake by 47% in Q2 2026, buying an estimated $19.7K and bringing the position to 12,551 shares worth $98.5K. The position accounts for ﹤0.01% of the portfolio, ranked #924.

SBI Securities first reported a position in ABCL in Q4 2024 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • SBI Securities held 12,551 shares of AbCellera Biologics worth $98.5K as of Q2 2026.
  • SBI Securities bought 4,023 AbCellera Biologics shares in Q2 2026, an estimated $19.7K.
  • AbCellera Biologics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #924 holding.
  • SBI Securities first reported a position in AbCellera Biologics in Q4 2024 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.